Bone marrow mesenchymal stem cells inhibit hepatic fibrosis via the AABR07028795.2/rno-miR-667-5p axis

Yuan Feng1†, Yanjie Li1†, Mingxing Xu1†, Hongyu Meng1, Cao Dai1, Zhicheng Yao2* and Nan Lin1*†

Abstract

Background: The mechanism of bone marrow mesenchymal stem cells (BMSCs) in treating hepatic fibrosis remains unclear.

Methods: TGF-β1-induced hepatic stellate cell (HSC)-T6 and CCl4-induced hepatic fibrosis rats were treated with BMSCs. HSC-T6 cell activity was determined using the cell counting kit-8 assay, and the histology change was evaluated using hematoxylin and eosin and Masson staining. The expression of fibrosis markers was determined using real-time quantitative PCR, Western blotting, and immunocytochemistry. RNA sequencing (RNA-seq) was used to screen the lncRNAs involved in the effect of BMSCs in fibrosis, and the function of fibrosis-associated lncRNA in fibrosis histology change and fibrosis marker expression was investigated. The potential miRNA target of lncRNA was predicted using R software. The interaction between lncRNA and miRNA was verified using luciferase report system and RNA immunoprecipitation (RIP) in 293T and HSC-T6 cells.

Results: BMSC attenuated TGF-β1-induced HSC-T6 activation and suppressed the expression of fibrosis-associated gene (MMP2, Collagen I, and αSMA) expression at the transcription and translation levels. BMSC treatment also improved hepatic fibrosis in rats with CCl4-induced fibrosis by decreasing the expression of fibrosis-associated genes and suppressing collagen deposition in the liver. RNA-seq revealed that AABR07028795.2 (lnc-BIHAA1) was downregulated in the TGF-β1-induced HSC-T6 after treatment with BMSCs as compared with those in TGF-β1-induced HSC-T6, and subsequently, functional analysis showed that lnc-BIHAA1 plays a beneficial role in suppressing hepatic fibrosis. Luciferase activity assay and RIP revealed that lnc-BIHAA1 interacted with the miRNA, rno-miR-667-5p, functioning as a fibrosis phenotype suppressor in TGF-β1-induced HSC-T6. Moreover, overexpression of rno-miR-667-5p significantly reverses the effect of lnc-BIHAA1 on HSC-T6.

Conclusions: BMSC treatment suppresses hepatic fibrosis by downregulating the lnc-BIHAA1/rno-miR-667-5p signaling pathway in HSCs. Our results provide a scientific basis for establishing BMSCs as a biological treatment method for liver fibrosis.

Keywords: Hepatic fibrosis, BMSCs, Hepatic stellate cells, lncRNA, miR-667-5p

Introduction

Hepatic fibrosis is a typical response to various chronic liver injuries causing viral hepatitis and alcohol toxicity, which results in the overproduction of extracellular matrix (ECM), ultimately leading to an imbalance between the production and dissolution of ECM [1]. Regarding cells in the liver, hepatic stellate cells (HSCs)
are the dominant collagen-producing cells and play a pivotal role in the occurrence and progression of hepatic fibrosis [2]. Therefore, the activation and proliferation of HSCs are considered key events in the process of hepatic fibrosis. A therapeutic strategy based on suppressing HSC activation and proliferation theoretically reduces the development and progression of hepatic fibrosis [3].

Over the past decades, numerous studies have contributed their efforts to search for therapy for hepatic fibrosis. Cell therapy, especially mesenchymal stem cell therapy, is one of the promising therapies. Since stem cells are easily isolated from the bone marrow, they have low immunogenicity and have high self-renewal and pluripotent differentiation potential, which has practical advantages in tissue regeneration [4–7]. Several animal experiments have shown that bone marrow mesenchymal stem cell (BMSC) treatment has the effects of anti-fibrosis, improving symptoms and liver function, suggesting the effectiveness and safety of BMSCs in clinical applications. However, its internal regulation mechanism is still unclear.

lncRNA is a class of noncoding RNA with a size of more than 200 nucleotides [8]. Increasing studies have suggested that lncRNAs are frequently dysregulated in various physiological and pathological processes and involved in cancer initiation and progression [9], metabolic diseases [10], and inflammation disease [11, 12]. Emerging evidence suggests that lncRNAs are involved in cellular mechanisms and therapeutic targets to treat hepatic fibrosis. By regulating the pyroptosis of macrophages [13], activating the classic pro-fibrosis pathway [14], or acting as a miRNA sponge, it exerts an anti-fibrosis function by inhibiting the miRNA-mediated fibrosis pathway [15–18]. However, the role and biological mechanisms of the vast majority of lncRNAs in the development and progression of hepatic fibrosis are still largely unknown. In addition, the involvement of lncRNA in treating BMSCs also needs to be studied further.

In this study, we analyzed the anti-fibrosis effect of BMSCs in both TGF-β1-induced liver stellate cell lines and rats with hepatic fibrosis phenotype. Further, we analyzed the biological mechanism underlying the BMSC treatment from the perspective of the lncRNA–miRNA interaction. Our findings might provide evidence for BMSCs in treating hepatic fibrosis and add new knowledge of the role of the lncRNA/miRNA axis in the process of hepatic fibrosis.

Materials and methods
Cell culture and BMSC treatment
A rat liver stellate cell line, HSC-T6, a human endothelial kidney cell line, HEK293T, and BMSCs were used. HSC-T6 cell lines were purchased from Procell Life Science and Technology Co., Ltd. (Wuhan, China). BMSCs were purchased from Guangzhou SALIAI Stem cell Science and Technology Co., Ltd. HEK293T cell lines were purchased from the National Collection of Authenticated Cell Cultures. HSC-T6 and HEK293T cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, USA) with high glucose (4500 mg/L), 10% fetal bovine serum (Gibco), 100 U/mL penicillin, and 100 g/mL streptomycin (Gibco) and cultured in an incubator containing 5% CO₂ at 37 °C. BMSCs were maintained in a stem cell-specific medium purchased from Guangzhou SALIAI Stem cell Science and Technology Co., Ltd. (SALIAI, G03010). For TGF-β1 induction, HSC-T6 cells were induced with TGF-β1 (2 or 10 ng/ml) for 24 h. For evaluating the therapeutic effects of BMSC treatment, HSC-T6 cells were grown in the lower chamber of a transwell system and induced with TGF-β1 (10 ng/ml) before co-culture. After 24 h of induction, BMSCs were seeded on the upper chamber and co-cultured with HSC-T6 for 72 h.

Hepatic fibrosis rat model construction and BMSC treatment
Rats (male SD rats, weighing approximately 130 ± 10 g) were purchased from the Guangdong Medical Experimental Animal Center (Guangzhou, China). Hepatic fibrosis rats were induced with CCl4 (1 mL/kg, CCl4: olive oil, v/v = 1:1) using intraperitoneal injections twice each week over 8 weeks. Referring to the previous studies [19, 20], the effect of BMSC treatment on hepatic fibrosis rats was evaluated by injecting the BMSCs (1 × 106 cells per rat) into the right lobe of the liver. After BMSC treatment, rats continue to feed for 3 weeks. Hepatic fibrosis rats without BMSC treatment/injected with PBS control were used as a sham and negative control. To investigate the effect of a knockdown on the lnc-BIHAA1 on hepatic fibrosis, lentivirus-based sh-lnc-BIHAA1 and control vectors were constructed and packaged (GenePharma, Shanghai, China) according to standard protocols. Two weeks after the CCl4 injection mentioned above, the resultant sh-lnc-BIHAA1 and control virus (6 × 107 TU/ rat/200 μl) was injected into rats through the tail vein. At week 11, the liver tissue was collected for subsequent experiments. This experiment was approved by the ethical committee of Guangzhou Foreverygen Biosciences (Guangzhou, China).

Cell counting kit-8 (CCK-8) assay
Approximately 4 × 10³ cells were cultured in a 96-well plate before the CCK-8 assay. Cells that received corresponding treatment continued to culture for 24, 48, and 72 h. CCK-8 reagent (Beyotime) was added to cells according to the manufacturer’s instructions for cell
activity measurement. The absorbance value at 450 nm on a microplate reader was recorded (BioTek, Vermont, USA).

**Western blotting (WB)**

Total proteins were extracted from HSC-T6 cells by RIPA (Beyotime, Shanghai, China) supplemented with phenylmethylsulfonyl fluoride. The proteins were separated with sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred onto the PVDF membranes. After blocking with 5% defatted milk powder, the membranes were incubated with primary antibodies of MMP2 (1:1000, Abcam, ab97779), anti-alpha smooth muscle (α-SMA, 1:1000, Boster, bm0002), collagen I (1:1000, Proteintech, 14695-1-AP), and GAPDH (1:2000, Proteintech, 60004-1-lg) at 4 °C overnight. The next day, membranes were incubated with secondary horseradish peroxidase-labeled secondary antibody (1:5000, Zhongshan Biotechnology, Beijing, China) at room temperature for 1 h. An enhanced chemiluminescence detection system (GE Health Care, Waukesha, USA) was used to visualize the proteins. The relative expression of proteins was normalized to that of the internal control GAPDH.

**Real-time quantitative PCR (qRT-PCR)**

Total RNA was extracted from HSC-T6 cells or liver tissue using TRizol reagent (Invitrogen, USA). cDNA was synthesized using Prime Script RT reagent kit (Takara, Tokyo, Japan). Power SYBR Green PCR Master Mix (Bio-Rad) was used for gene amplification according to the manufacturer’s instructions. qRT-PCR was performed on an ABI7500 Real-Time PCR System, and the relative gene expression was calculated using the 2^-ΔΔCT method. GAPDH was used as an internal control. The primers used in this study are shown in Table 1.

**Immunohistology assay**

Paraffin-embedded sections of 5 μm thickness were dehydrated and stained with hematoxylin and eosin (HE) and Alcian blue. To evaluate the expression of MMP2, collagen I, and α-SMA, the sections were placed in an antigen repair solution buffer (pH 9.0) and then blocked in 2% normal goat serum. Afterward, sections were incubated with primary antibodies, including anti-MMP2 antibody (Abcam), α-SMA (Boster), and collagen I (Proteintech) antibody. Signals were detected using the VECTASTAIN ABC Elite Kit (Vector Laboratories, CA, USA), followed by DAB Substrate Kit (Vector Laboratories) according to the manufacturer’s instructions.

**Hematoxylin and eosin (HE) and Masson’s trichrome staining**

Liver tissue sections of 5 μm thickness were separately stained with hematoxylin and eosin (HE) and Masson’s trichrome. The morphological changes and collagen content were observed using microscopy (Nikon 80i, Tochigi, Japan).

**RNA sequencing (RNA-seq) and lncRNA expression analysis**

To draw lncRNA expression profiles, total RNA was qualified and fragmented. A cDNA library was prepared using the SmartPCR cDNA kit (CLONTECH Laboratories, Japan) and subjected to RNA-seq for lncRNA using an Illumina HiSeq2000 perform (BGI-Shenzhen, Shenzhen, China). To analyze the differential expression of lncRNA, raw data were mapped to a rat reference genome, and the differentially expressed lncRNAs were identified using Cufflinks v.2.0.2 with default parameters. The significantly different expressed lncRNAs were defined by the following criterion: |log2Ratio| ≥ 0.67, P value < 0.05.

| Table 1 Primers and oligonucleotides used in this study |
| --- |
| Primer name | Sequence (5’-3’) |
| AABR07069008.3-F | CTGCCACGACACCATCGTTA |
| AABR07069008.3-R | AGGTTAGGAGAGAGACCAT |
| LOC103692471-F | AGGTGACTACGGCTTCGTC |
| LOC103692471-R | GGACTTTTCTTACGATTC |
| AC095078.2-F | GAGAGTCCGCTGACTTG |
| AC095078.2-R | TGTCACCTGACACATCATT |
| AC139608.2-F | ATGACTGAGCTGGCTT |
| AC139608.2-R | CCAAGTGCTGGTACTTGT |
| AABR07028795.2-F | CACTTCTGGCCAGCTTCAT |
| AABR07028795.2-R | CTTTGTCTTGTACATTG |
| Rat-α-SMA-F | ACCATCGGGAATGACGCTT |
| Rat-α-SMA-R | CTGTCAGCAATGGCTGGTA |
| Rat-COL1(Collagen I)-F | GGAGAGGACGATGGAGGT |
| Rat-COL1(Collagen I)-R | GGACTTCTGGAGTGTC |
| Rat-Mmp2-F | AGCTTGTGAGTCCTATC |
| Rat-Mmp2-R | GGAATGACGTCGATGG |
| Rat-GAPDH-F | GCAAAGAGAGAGGCTCAG |
| Rat-GAPDH-R | TGGATGAGGAGATGGT |
| Si-Rat-AABR07028795.2-1 | GCTGAGACACGTCGACTA |
| Si-Rat-AABR07028795.2-2 | GCACAGATCCAGAAGT |
| Si-Rat-AABR07028795.2-3 | CCGTAGAATAATGAGC |
| siRNA-NC | UUUCUGAACGAGUACGUTT |
| Rno-miR-667-5p mimics (5’-3’) | CGGUGCUGGUGGAGACAGUAGAC |
| Rno-miR-667-5p inhibitor (5’-3’) | GUGGUCUGACUCUCACAGACAGC |
| miRNA mimics NC (5’-3’) | UUUCUGAACGAGUACGUTT |
| miRNA inhibitor NC (5’-3’) | ACGUGACACGUGUGAGAAGUA |
The potential function of differentially expressed IncRNAs and possible pathways that might be involved was predicted using the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) platform (http://www.genome.jp/kegg/) analyses using R package. The IncRNA–miRNA interaction was predicted by the R package and visualized by Cytoscape software.

Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL assay) and immunofluorescent staining

TUNEL assay was conducted similar to the immuno-histology assay. Sections were stained according to the protocol of A Click-it TUNEL Alexa Fluor 488 Imaging Assay (Invitrogen) and incubated with the primary antibodies (1:100, Proteintech, #16520-1-AP) with a subsequent incubating with corresponding secondary antibody (1:1000, Invitrogen, #A11012). Cell nuclei were stained with DAPI. Fluorescent images were observed under a fluorescence microscope (Olympus, Tokyo, Japan).

Fluorescent in situ Hybridization (FISH)

FISH was performed using the Fluorescent in situ Hybridization Kit according to the manufacturer's instructions (Thermo Fisher, Shanghai, China). Cells cultured on coverslips (18-mm round) were fixed with 4% formaldehyde and treated with PBS containing 0.5% Triton X-100. After blocking, cells were incubated in hybridization solutions (2 × SSC, 100 mg/ml dextran sulfate, and 10% formamide) containing AABR07028795.2-specific 6-FAM-labeled probe (BersinBio, Guangdong Province, China) at 37 °C overnight in a humidified chamber. The slides were washed with 4 × SSC, 2 × SSC, and 1 × SSC for 5 min each. Finally, the coverslips were counterstained with DAPI. The signal was observed under fluorescence microscopy.

Hyaluronic acid (HA), hydroxyproline (HYP), and liver function indicators measurement

For liver tissues HYP and HA measurement, the kits for HYP (#A030-2-1; Jiancheng Bioengineering Institute, Nanjing, China) and HA (#H141-1-2; Jiancheng Bioengineering Institute) were used. The serum levels of liver function indicators including alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), and albumin (ALB) were determined by kit from Jiancheng Bioengineering Institute (corresponding product number: #C009-2-1, #C010-2-1, #C019-1-1, and #A028-2-1) following the manufacturer’s instructions.

Cell transfection

HSC-T6 cells (5 × 10^5 cells) were seeded on 6-well plates before transfection. The cell medium was replaced with serum and antibiotic-free DMEM. siRNAs targeting AABR07028795.2, rno-miR-667-5p mimic/inhibitor (GenePharma, Shanghai, China), and AABR07028795.2 overexpressing vector (GENERAL BIOL, Chuzhou, China) were transfected into cells using Lipofectamine 2000 transfection reagent (Invitrogen, MA, USA). Scramble siRNA/miRNA mimic/inhibitor and an empty vector were used as a negative control. The sequence of siRNA, miRNA mimics, and miRNA inhibitors is listed in Table 1.

Luciferase activity assay

Wild-type (WT) or mutated fragments of AABR07028795.2 were subcloned into the luciferase reporter plasmid pmirGLO luciferase vector (Promega, USA), resulting in WT (AABR07028795.2 WT) and mutant (MUT) plasmids (AABR07028795.2 MUT1 and AABR07028795.2 MUT2). The WT and MUT plasmids were co-transfected with rno-miR-667-5p mimics or miRNA mimic NC. After 24 h, luciferase activity was determined using the dual-luciferase reporter assay system (Promega, USA).

RNA immunoprecipitation (RIP) assay

The relationship between AABR07028795.2 and rno-miR-667-5p was analyzed using the Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, USA). The co-precipitated RNAs were purified and transcribed to cDNA for qRT-PCR analysis. Primers specific for AABR07028795.2 and rno-miR-667-5p were used for qPCR. Antibodies used in RIP assay included anti-AGO2 and control IgG (Millipore, USA).

Statistics

Data were presented as mean ± standard deviation (SD). The data were analyzed using GraphPad Prism software v.7.0 (GraphPad Software, San Diego, CA, USA). Differences between groups were analyzed using Student’s t test. A one-way or two-way analysis of variance was used for the comparison of more than three groups. P<0.05 was considered statistically significant.

Results

BMSCh treatment attenuates fibrotic phenotype of TGF-β1-induced HSC-T6 cells and hepatic fibrosis rats

In order to study the effect of TGF-β1 on the proliferation and fibrotic phenotype of HSC-T6 cells, cells were treated with different concentrations of TGFβ1 (2 ng/mL and 10 ng/mL). CCK-8 assay was performed to detect cell viability at 24, 48, and 72 h after TGF-β1 treatment. It was found that TGF-β1 stimulation significantly increased the cell viability of HSC-T6 cells in a concentration-dependent manner, and as time increased, cell viability increased (Fig. 1A). qRT-PCR and WB showed...
that the fibrosis marker, MMP2, α-SMA, and collagen I mRNA and protein expression increased HSC-T6 cells treated with TGF-β1 for 24 h in a concentration-dependent manner (Fig. 1B and C). However, when HSC-T6 cells were co-cultured with BMSCs, BMSC treatment significantly inhibited the proliferation of HSC-T6 cells (Fig. 1D). Simultaneously, BMSC treatment for 72 h significantly inhibited the upregulation of mRNA and protein expression of MMP2, α-SMA, and collagen I induced by TGF-β1, as evidenced by qRT-PCR, WB, and IHC assays (Fig. 1E–G).

To investigate the effects of BMSCs on hepatic fibrosis rats, rats were first induced with CCl4 and treated with BMSCs. Hyp and HA contents in liver tissues, and serum ALT, AST, and TBIL was significantly upregulated in CCl4-induced rats (the hepatic fibrosis group), whereas BMSC injection (the hepatic fibrosis + BMSC group) significantly reversed the upregulation of these indicators caused by CCl4 (Fig. 2A–E). In contrast, the serum level of ALB was significantly reduced in the hepatic fibrosis group, which was reversed by BMSC treatment (Fig. 2F). BMSCs also alleviate the structural damage to the liver. H&E and Masson staining showed that collagen deposition in liver tissue was significantly upregulated in the hepatic fibrosis group and was downregulated in the presence of BMSC treatments. As shown in Fig. 2G, the liver lobule structure in the rats of the sham group is clear and complete, hepatocyte cords are arranged radially from the central vein to the surroundings, and dilated hepatic sinusoids and collagen fibers were not observed; also, inflammatory cell infiltration or collagen fiber proliferation was not found. Compared with sham rats, the rats’ liver lobules in the liver tissue of hepatic fibrosis rats and those with hepatic fibrosis with PBS treatment were disordered, the structure of liver cells was destroyed, the fibrous connective tissue was proliferated, and most of the hepatocytes showed lamella necrosis, forming a typical pseudo-lobular structure of different sizes. The pseudo-lobules were mainly filled with fatty liver cells, with an increase in necrotic cells. However, liver injury was alleviated in BMSC-treated rats. Compared with the hepatic fibrosis rats, the liver lobule-like structure in the liver is normal, and there is not much collagen fiber proliferation.

In addition to studying the effect of BMSCs on pathological liver changes, we used qRT-PCR and IHC to detect the expression of fibrosis markers in the livers of rats with or without BMSC injection treatment. Both qRT-PCR and IHC results showed that the expression of MMP2, α-SMA, and collagen I in the liver tissue of fibrotic rats and PBS-treated fibrotic rats increased significantly compared with the sham group but was partially downregulated in the BMSC treatment group (Fig. 2H and I). Desmin was used as a marker to identify HSCs [21]. The TUNEL and desmin colocalization assay further showed that BMSC treatment significantly
increased the apoptotic rate of desmin-positive cells in the liver tissue of the rats (Fig. 2J).

**AABR07028795.2 suppresses the TGF-β1-induced fibrotic phenotype of HSC-T6 cells**

To study the molecular mechanism of the inhibitory effect of BMSCs involved in hepatic fibrosis, TGF-β1-induced HSC-T6 cells with or without BMSC treatment were subjected to RNA-seq for analyzing the expression of IncRNAs in HSC-T6 in response to BMSC treatment. As shown in Fig. 3, RNA-seq results showed that all IncRNAs aligned to the genome were distributed on all chromosomes (Fig. 3A). Further analysis of the distributions of differentially expressed IncRNA showed that the upregulated IncRNAs were distributed on all chromosomes except chr14. The downregulated IncRNA is distributed on chromosomes, except for chr2, chr7, chr11, chr14, and chr15 (Fig. 3B). Using heat maps to visualize
Fig. 3 (See legend on previous page.)
the expression profile of lncRNA found that a total of 103 lncRNA expressions changed significantly, of which 72 lncRNA expressions were upregulated and 31 lncRNA expressions were downregulated (Fig. 3C). Overall, the expression patterns of lncRNA in BMSC-treated cells were different from those without BMSC treatment. To predict the potential function of these lncRNAs, GO and KEGG analysis was performed. As shown in Fig. 3, GO analysis shows that the differentially expressed lncRNA is involved in cell apoptosis, cell proliferation, and EMT (fibrosis) transformation of GO term (Fig. 3D). KEGG enrichment analysis showed that differentially expressed lncRNA is mainly involved in the PI3K-AKT, FoxO, Ras, cAMP, and MAPK signaling pathways (Fig. 3E).

To verify the abundance of differentially expressed lncRNA found in RNA-seq, five of the top 10 differentially expressed lncRNAs with a length between 650 and 2000 bp, FDR < 0.05, and specific fragment regions were verified using qPCR in TGF-β1-induced HSC-T6 cells with or without BMSC treatment. Consistent with the RNA-seq results, the qPCR results showed that, of the five lncRNAs, AC095078.2, AC139608.2, AABR0702879.2, AABR07069008.3, and LOC103692471, which were differentially expressed in BMSC-treated cells (Fig. 3F), we selected two lncRNAs that are significantly upregulated and downregulated for follow-up experiments. The results showed that only AABR07028795.2 (namely lnc-BIHAA1) was also downregulated in BMSC-treated fibrotic rats (Fig. 3G). lnc-BIHAA1 was chosen for subsequent functional analysis.

To analyze the function of lnc-BIHAA1 in vitro, HSC-T6 cells first interfered with lnc-BIHAA1 siRNAs. qPCR results showed that si-lnc-BIHAA1-3 has the most evident interference effect among the three lnc-BIHAA1 siRNAs (Fig. 3H). CCK-8 assay results showed that compared with siNC, si-lnc-BIHAA1 transfection significantly reduced the increase in cell viability induced by TGF-β1 at 48 and 72 h after siRNA transfection (Fig. 3I) and suppressed the fibrosis markers, MMP2, collagen I, and α-SMA mRNA (Fig. 3J), and protein (Fig. 3K and L) expression. FISH results revealed that lnc-BIHAA1 is mainly located in the cytoplasm (Fig. 3M).

In contrast, overexpressed lnc-BIHAA1 (Fig. 4A) reversed the BMSC inhibition effect on the HSC-T6 activity, enhanced by the TGF-β1 treatment (Fig. 4B). Simultaneously, the inhibitory effect of BMSCs on MMP2, collagen I, α-SMA mRNA (Fig. 4C), and protein (Fig. 4D and E) was also reversed.

**Fig. 4** Lnc-BIHAA1 attenuated the beneficial effect of BMSCs on the activation of HSC-T6 induced by TGF-β1. A The overexpression efficiency of the lnc-BIHAA1 vector. **B** CCK-8 showed the effect of lnc-BIHAA1 overexpression on the activity of TGF-β1-induced HSC-T6 cells with or without BMSCs. **C** qPCR (C), WB (D), and IHC (E) assay showing the effect of lnc-BIHAA1 overexpression on the expression of fibrosis markers in TGF-β1-induced HSC-T6 cells with or without BMSCs. Magnification, 200x.
lnc-BIHAA1 suppresses hepatic fibrosis via targeting rno-miR-665

The ceRNA mechanism that targets miRNA and affects miRNA function is a molecular mechanism by which lncRNA regulates biological functions. To find the potential target miRNAs of lnc-BIHAA1, we built...
lnc-BIHAA1 as the center point and used the miRNAs, predicted by bioinformatics as a secondary connecting node to construct the lnc-BIHAA1-miRNA interaction network (Fig. 5A). According to the number of binding sites, five key miRNAs were selected for further expression verification. The qPCR results showed that the expressions of rno-miR-665, rno-miR-667-5p, and rno-miR-742-3p were significantly decreased in HSC-T6 cells after lnc-BIHAA1 overexpression, which matches the ceRNA regulation mode (Fig. 5B). Among them, rno-miR-667-5p is downregulated in liver tissue samples of hepatic fibrosis rats (Fig. 5C), suggesting that rno-miR-667-5p is a downstream molecule regulated by lnc-BIHAA1.

To answer whether rno-miR-667-5p is involved in regulating liver fibrosis, first, HSC-T6 cells were transfected with rno-miR-667-5p mimic and rno-miR-667-5p inhibitor to overexpress and inhibit rno-miR-667-5p expression (Fig. 5D and H). Then, the cells were stimulated with TGF-β1. CCK-8 assay results showed that rno-miR-667-5p mimic significantly inhibited the increase in cell viability induced by TGF-β1 treatment for 48 and 72 h (Fig. 5E), while rno-miR-667-5p inhibitor was opposite to the rno-miR-667-5p mimic (Fig. 5I). qPCR results show that miR-667-5p mimic inhibits TGF-β1-induced mRNA (Fig. 5F) and protein expression (Fig. 5G and L) of MMP2, collagen I, and α-SMA in HSC-T6. In contrast, miR-667-5p inhibitor promoted the mRNA (Fig. 5J) and protein expression (Fig. 5K and M) of these genes.

To explore the relationship between rno-miR-667-5p and lnc-BIHAA1, rno-miR-667-5p mimic was transfected into lnc-BIHAA1 overexpressing HSC-T6 cells. As shown in Fig. 6, rno-miR-667-5p mimic significantly inhibited the increase in HSC-T6 cell viability at 24, 48, and 72 h post-transfection (Fig. 6A) and inhibited MMP2, collagen I, and α-SMA mRNA (Fig. 6B) and protein expression (Fig. 6C and D). Luciferase assay revealed that only the luciferase activity of the vector containing WT lnc-BIHAA1 sequence was inhibited by rno-miR-667-5p mimics, while the luciferase activity of vector harboring MUT lnc-BIHAA1 did not change significantly (Fig. 6E). Further RIP assay verified that significantly increased rno-miR-667-5p was observed in the Ago2 complex in cells overexpressing lnc-BIHAA1, suggesting increased recruitment of rno-miR-667-5p into RNA-induced silencing complex in the case of lnc-BIHAA overexpression (Fig. 6F).

The qRT-PCR results showed that the expression of lnc-BIHAA1 was significantly downregulated in rats injected with sh-lnc-BIHAA1 (Fig. 7A), whereas rno-miR-667-5p was significantly upregulated (Fig. 7B). The results of H&E and Masson staining showed that inhibiting the expression of lnc-BIHAA1 attenuated liver fibrosis: the liver cell structure in the liver tissue of

![Fig. 6 Lnc-BIHAA1 binds and suppresses rno-miR-665 expression to promote liver fibrosis in HSC-T6 cells. A CCK-8 assay showing the inhibitory effects of rno-miR-667-5p mimics on cell activity in lnc-BIHAA1 overexpressing cells. The relative expression of fibrosis-associated genes mRNA and protein detected by qPCR (B), WB (C), and IHC (D). Magnification, 200x. Luciferase activity assay (E) and RIP assay (F) show the interaction between lnc-BIHAA1 and rno-miR-665](image-url)
the sh-NC group was destroyed, and the collagen fibers were prominent, whereas in the liver tissue of the sh-lnc-BIHAA1 group, the morphology of liver cells was normal, the lobular structure of the liver was normal compared with the sh-NC group, and the hyperplasia of collagen fibers was less (Fig. 7C). TUNEL assay results showed that the apoptosis of liver tissues in the sh-lnc-BIHAA1 group was significantly increased compared with that of the sh-NC group (Fig. 7D). In addition, the expression of MMP2, collagen I, and α-SMA protein in liver tissue was significantly reduced by IHC (Fig. 7E) in the sh-lnc-BIHAA1 group. The results showed that compared with the sh-NC group, the expression of ECM-related proteins in the sh-lnc-BIHAA1 group were significantly reduced.

**Discussion**

This study found the anti-fibrotic effects of BMSC treatment on TGF-β1-induced HSC-T6 cells and CCl4-induced hepatic fibrosis rats. A further mechanism study revealed that lnc-BIHAA1, which was downregulated by BMSC treatment, suppressed hepatic fibrosis by binding to rno-miR-667-5p and upregulated the expression of rno-miR-667-5p to inhibit fibrosis.

HSC is the primary source of ECM that contributes to fibrosis significantly. Overproduction of ECM is the primary pathological feature of hepatic fibrosis [22]. HSC is in quiescent status in the normal liver, and the production and degradation of ECM are balanced. However, when the HSC is activated into a myofibroblast-like phenotype by inflammation or cytokines, the ECM is overexpressed, and the expression of α-SMA
is upregulated [2] and leads to the distortion of normal liver architecture. TGFβ has been proven as a pro-fibrotic cytokine. Notably, HSC activation is supported by TGF-β [23]. TGF-β1 can promote and maintain the expression of collagen genes and affects resisting HSC cell apoptosis [24]. In this study, we used TGF-β1 to induce HSC-T6 cells. As expected, cell activation of HSC6 was increased, indicating an increase in cell proliferation of HSC. Also, increased ECM and myofibroblast-like phenotype were observed in the cells, which indicated the activation of HSCs and acquisition of the pro-fibrosis phenotype.

BMSC treatment has been suggested to be a promising therapy for fibrosis. However, the underlying mechanism still needs to be investigated. IncRNA has the function of regulating liver fibrosis. IncRNA mainly enhances the pyroptosis of macrophages, inhibits the classic pro-fibrosis pathway, and inhibits HSC activation to alleviate liver fibrosis [25]. Although IncRNA related to liver fibrosis has been reported in many studies, as reported in the literature review [26]. However, the regulatory function of a large number of IncRNAs in liver fibrosis and whether the effect of BMSCs is associated with IncRNA remain to be studied. In our study, we found that Inc-BIHAA1 has the function of promoting liver fibrosis. As of our best knowledge, few studies have been reported regarding the function of Inc-BIHAA1. Thus, our research has increased the understanding of IncRNA in regulating liver fibrosis. We also suggest that Inc-BIHAA1 is one of the effector molecules of BMSC therapy.

miRNA is involved in regulating the formation and progression of liver fibrosis. Both endogenous and extracellular vesicles have the role of repairing injured tissue and suppressing fibrosis [27–29]. Of the miRNAs, microRNA-29b is an important regulator of liver fibrosis. Many studies have revealed that microRNA-29b regulates the level of gene methylation modification and inhibits liver fibrosis by inhibiting HSC cell activation [30–32]. Also, microRNA-17-5p, microRNA-222, and microRNA-221-3p have been shown to promote fibrosis [33–35], and microRNA-378 and microRNA-101 inhibit HSC activation in liver fibrosis [36, 37]. We found that rno-miR-667-5p inhibited the increase in HSC-T6 cell viability caused by the expression of Inc-BIHAA1 and inhibited the expression of fibrosis markers. As there is still a lack of extensive research on the function of rno-miR-667-5p, our research also suggests new molecules for miRNA to regulate liver fibrosis. In addition, our research also suggests new molecules still a lack of extensive research on the function of rno-miR-667-5p. Further analysis found that rno-miR-667-5p can reverse the promoting effect of Inc-BIHAA1 on the fibrous phenotype of HSC-T6 at the cellular level. In addition, animal experiments also found that Inc-BIHAA1 in rat fibrotic liver tissue was downregulated after BMSC treatment, whereas rno-miR-667-5p was upregulated. These results suggest that the interaction of Inc-BIHAA1 and rno-miR-667-5p has an anti-fibrosis effect.

RNA-induced silencing complex is a complex for gene silencing. RNA interference is triggered by signals, such as dsRNA and ribonucleoprotein. For example, Argonaute 2, a key component of RNA-induced silencing complex, binds to small regulatory RNA and is guided to target downstream transcripts [45]. This study first found the potential biding site of rno-miR-667-5p and Inc-BIHAA1 using luciferase assay. Mainly, rno-miR-667-5p and Inc-BIHAA1 was observed in the AGO2 immunoprecipitated complex, and the abundance of rno-miR-667-5p was increased, accompanied by Inc-BIHAA1 expression. These results suggest that Inc-BIHAA1 upregulation promotes the recruitment of rno-miR-667-5p into the RNA-induced silencing complex, guided by RNA and silencing gene expression [46]. Combining the different functions of rno-miR-667-5p and Inc-BIHAA1 in liver fibrosis and their interactions, we believe that BMSC therapy may exert anti-fibrotic effects by regulating the Inc-BIHAA1/rno-miR-667-5p axis.

**Conclusions**

We found that BMSCs alleviate liver fibrosis, inhibit the activation of HSC induced by TGF-β1, and promote apoptosis. One possible mechanism is to inhibit the expression of Inc-BIHAA1, thereby inhibiting its binding to downstream rno-miR-667-5p and enhancing the
anti-fibrosis function of rno-miR-667-5p. Our research provides a molecular mechanism of BMSCs in treating liver fibrosis and provides a theoretical basis for promoting the clinical application of BMSCs in treating liver fibrosis.

Abbreviations
BMSCs: Bone marrow mesenchymal stem cells; ECM: Extracellular matrix; HSCs: Hepatic stellate cells; CCK-8: Cell counting kit-8; WB: Western blotting; qRT-PCR: Real-time quantitative PCR; HE: Hematoxylin and eosin; RNA-seq: RNA sequencing; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; TUNEL: Transferase dUTP nick end labeling; FISH: Fluorescent in situ hybridization; HA: Hyaluronic acid; HYP: Hydroxyproline; WT: Wild type; MUT: Mutant; RIP: RNA immunoprecipitation; SD: Standard deviation.

Acknowledgements
Not applicable.

Author contributions
YEYL, ML, HM, CD, ZY, and NY conceived the project and designed the study; YEYL and MX drafted the manuscript; YEYL, ML, HM, and CD performed the experiments; HM, CD, ZY, and NY analyzed the data; ZY and NY organized the figures, acquired the financial support, and edited the manuscript. All authors approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China under Grant [number 82002544, 81760112, 82100560]; Science and Technology Planning Project of Guangzhou City under Grant [number 202102010171]; Chinese Foundation for Hepatitis Prevention and Control-TianQin Liver Disease Research Fund Subject under Grant [number TQGB20200048]; CSCS-Roche Solid Tumor Research Project under Grant [number Y-Roche2019/2-7-0041]; and Medical Scientific Research Foundation TianQing Liver Disease Research Fund Subject under Grant [number TQGB20200048].

Availability of data and materials
The data used to support the findings of this study are available from the corresponding author upon request.

Declarations

Ethics approval and consent to participate
This experiment was approved by the ethical committee of Guangzhou Foregen Biosciences (Guangzhou, China). This experiment was approved by the ethical committee of Guangzhou Foregen Biosciences (Guangzhou, China).

Consent for publication
Not applicable.

Competing interests
The authors declare no competing interests.

Received: 29 July 2021 Accepted: 20 July 2022 Published online: 28 July 2022

References
1. Wang X, Hu F, Hu X, Chen W, Huang Y, Yu X. Proteomic identification of potential Clonorchis sinensis excretory/secretory products capable of binding and activating human hepatic stellate cells. Parasitol Res. 2014;113(8):3063–71.
2. Huang Y, Dong X, Liang J. Modulation of hepatic stellate cells and reversibility of hepatic fibrosis. Exp Cell Res. 2017;352(2):420–6.
3. Ezhilarasan D, Sokal E, Najimi M. Hepatic fibrosis: It is time to go with hepatic stellate cell-specific therapeutic targets. Hepatobiliary Pancreat Dis Int. 2018;17(3):192–7.
4. Terai S, Ishikawa T, Omon K, Aoyama Y, Muramoto Y, Uraya Y, et al. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells. 2006;24(10):2292–8.
5. Hwang S, Hong HN, Kim HS, Park SR, Won YJ, Choi ST, et al. Hepatogenic differentiation of mesenchymal stem cells in a rat model of thioacetamide-induced liver cirrhosis. Cell Biol Int. 2012;36(3):279–88.
6. Duman DG, Zibande NH, Uguuru MU, Celikel C, Akkoç T, Banzragch M, et al. Mesenchymal stem cells suppress hepatic fibrosis accompanied by expanded intrahepatic natural killer cells in rat fibrosis model. Mol Biol Rep. 2019;46(3):2997–3008.
7. Abdel Aziz MT, Atta HM, Mahfouz S, Fouad HH, Rosshdy NK, Ahmed HH, et al. Therapeutic potential of bone marrow–derived mesenchymal stem cells on experimental liver fibrosis. Clin Biochem. 2007;40(12):893–9.
8. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861–74.
9. Huarte M. The emerging role of IncRNAs in cancer. Nat Med. 2015;21(11):1253–61.
10. Liu JY, Yao J, Li XM, Song YC, Wang XQ, Li YJ, et al. Pathogenic role of IncRNA-MALAT1 in endothelial cell dysfunction in diabetes mellitus. Cell Death Dis. 2014;5(10):e1505–16.
11. Yaran R, Mirza AH, Kaur S, Pociot F. The emerging role of IncRNAs in inflammatory bowel disease. Exp Mol Med. 2018;50(12):1–14.
12. Liao K, Xu J, Yang W, You X, Zhong Q, Wang X. The research progress of LncRNA involved in the regulation of inflammatory diseases. Mol Immunol. 2018;181:182–8.
13. Zhang K, Shi Z, Zhang M, Dong X, Zheng L, Li G, et al. Silencing IncRNA Lfarr1 alleviates the classical activation and pyroptosis of macrophage in hepatic fibrosis. Cell Death Dis. 2020;11(2):132–44.
14. Zhang K, Han X, Zhang Z, Zheng L, Hu Z, Yao Q, et al. The liver-enriched Inc-LFAR1 promotes liver fibrosis by activating TGFβ and Notch pathways. Nat Commun. 2017;8(1):144–59.
15. Dong Z, Li S, Wang X, Si L, Ma R, Bao L, et al. IncRNA GASS represses CCI(4)-induced hepatic fibrosis by targeting miR-23a through the PTEN/PKB/Akt signaling pathway. Am J Physiol Gastrointest Liver Physiol. 2019;316(4):G539–G550.
16. Fu N, Zhao SX, Kong LB, Du JH, Ren WG, Han F, et al. LncRNA-ATB/microRNA-200a/b-catenin regulatory axis involved in the progression of HCV-related hepatic fibrosis. Gene. 2017;618:1–7.
17. Zhou B, Yuan W, Li X. LncRNA Gm5091 alleviates alcoholic hepatic fibrosis by sponging miR-27b-23b/24 in mice. Cell Biol Int. 2019;43(10):1330–9.
18. Yu F, Liu Z, Cai J, Huang K, Chen B, Li G, et al. MALAT1 functions as a competing endogenous RNA to mediate Rac1 expression by sequestring miR-101b in liver fibrosis. Cell Cycle. 2015;14(24):3885–96.
19. Meier PP, Müller YD, Morel P, Gonelle-Gispert C, Bühler LH. Transplantation of mesenchymal stem cells for the treatment of liver diseases, is there enough evidence? Stem Cell Res. 2013;13(1):1384–69.
20. Xu W, Xu YN, Zhang X, Xu Y, Jian X, Chen JM, et al. Hepatic stem cell Numb gene is a potential target of Huang Qi. Decoction against cholestatic liver fibrosis. Sci Rep. 2020;10(1):17486–99.
21. Wang SL, Wu HM, He CZ, Yang L, Gao HJ, Yang CQ, Aldosterone and TGF-β1 synergistically increase PAI-1 expression in hepatic stellate cells of rats. Int J Clin Exp Pathol. 2015;8(9):9845–53.
22. Friedman SL. Liver fibrosis—from bench to bedside. J Hepatol. 2003;38(Suppl 1):S38–53.
23. El-Lakkany NM, Hammad OA, El-Maadawy WH, Badawy AA, Ebeid FA. Anti-inflammatory/anti-fibrotic effects of the hepatoprotective silymarin and the schistosomicide praziquantel against Schistosoma mansoni-induced liver fibrosis. Parasit Vectors. 2012;5:96–109.
28. Xiao B, Zhu Y, Huang J, Wang T, Wang F, Sun S. Exosomal transfer of bone marrow mesenchymal stem cell-derived miR-340 attenuates endometrial fibrosis. Biol Open. 2019;8(5):bio039958-039966.

29. Cai X, Wang L, Wang X, Hou F. miR-124a enhances therapeutic effects of bone marrow stromal cells transplant on diabetic nephropathy-related epithelial-to-mesenchymal transition and fibrosis. J Cell Biochem. 2020;121(1):299–312.

30. Wang J, Chu ES, Chen HY, Man K, Go MY, Huang XR, et al. microRNA-29b prevents liver fibrosis by attenuating hepatic stellate cell activation and inducing apoptosis through targeting PI3K/AKT pathway. Oncotarget. 2015;6(9):7325–38.

31. Zheng J, Wu C, Lin Z, Guo Y, Shi L, Dong P, et al. Curcumin up-regulates phosphatase and tensin homologue deleted on chromosome 10 through microRNA-mediated control of DNA methylation—a novel mechanism suppressing liver fibrosis. Febs J. 2014;281(1):88–103.

32. Yu F, Chen B, Dong P, Zheng J. HOTAIR epigenetically modulates PTEN expression via MicroRNA-29b: a novel mechanism in regulation of liver fibrosis. Mol Ther. 2017;25(1):205–17.

33. Yu F, Lu Z, Huang K, Wang X, Xu Z, Chen B, et al. MicroRNA-17-5p-activated Wnt/β-catenin pathway contributes to the progression of liver fibrosis. Oncotarget. 2016;7(1):81–93.

34. Shen WJ, Dong R, Chen G, Zheng S. microRNA-222 modulates liver fibrosis in a murine model of biliary atresia. Biochem Biophys Res Commun. 2014;446(1):155–69.

35. Tsay HC, Yuan Q, Balakrishnan A, Kaiser M, Mobus S, Kozdrowska E, et al. Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis. J Hepatol. 2019;70(4):722–34.

36. Huyun J, Wang S, Kim J, Rao KM, Park SY, Chung I, et al. MicroRNA-378 limits activation of hepatic stellate cells and liver fibrosis by suppressing Gli3 expression. Nat Commun. 2016;7:10993–1008.

37. Lei Y, Wang QT, Shen L, Tao YY, Liu CH. MicroRNA-101 suppresses liver fibrosis by downregulating PI3K/Akt/mTOR signaling pathway. Clin Res Hepatol Gastroenterol. 2019;43(5):575–84.

38. Sun X, Haider Ali MSS, Moran M. The role of interactions of long non-coding RNAs and heterogeneous nuclear ribonucleoproteins in regulating cellular functions. Biochem J. 2017;474(17):2925–35.

39. Simion V, Zhou H, Haemmig S, Pierce JB, Mendes S, Tesmenitsky Y, et al. A macrophage-specific IncRNA regulates apoptosis and atherosclerosis by tethering HuR in the nucleus. Nat Commun. 2020;11(1):6135–50.

40. Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013;339(2):159–66.

41. Zhang K, Shi ZM, Chang YN, Hu ZM, Qi HX, Hong W. The ways of action of long non-coding RNAs in cytoplasm and nucleus. Gene. 2014;547(1):1–9.

42. Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet. 2016;17(5):272–83.

43. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33.

44. Yu F, Guo Y, Chen B, Shi L, Dong P, Zhou M, et al. LincRNA-p21 inhibits the Wnt/β-catenin pathway in activated hepatic stellate cells via sponging MicroRNA-17-5p. Cell Physiol Biochem. 2017;41(5):1970–80.

45. Rand TA, Ginalska K, Grishin NV, Wang X. Biochemical identification of Argonauta 2 as the sole protein required for RNA-induced silencing complex activity. Proc Natl Acad Sci U S A. 2004;101(40):14385–9.

46. Pratt AJ, MacRae IJ. The RNA-induced silencing complex: a versatile gene-silencing machine. J Biol Chem. 2009;284(27):17897–901.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.